SNDX
Price
$16.63
Change
+$0.42 (+2.59%)
Updated
Nov 13 closing price
111 days until earnings call
YMAB
Price
$12.14
Change
-$1.04 (-7.89%)
Updated
Nov 14, 11:45 AM (EDT)
98 days until earnings call
Ad is loading...

SNDX vs YMAB

Header iconSNDX vs YMAB Comparison
Open Charts SNDX vs YMABBanner chart's image
Syndax Pharmaceuticals
Price$16.63
Change+$0.42 (+2.59%)
Volume$3.07M
CapitalizationN/A
Y-mAbs Therapeutics
Price$12.14
Change-$1.04 (-7.89%)
Volume$586
CapitalizationN/A
SNDX vs YMAB Comparison Chart
Loading...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
SNDX vs. YMAB commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SNDX is a Buy and YMAB is a Sell.

COMPARISON
Comparison
Nov 14, 2024
Stock price -- (SNDX: $16.64 vs. YMAB: $13.19)
Brand notoriety: SNDX and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SNDX: 247% vs. YMAB: 93%
Market capitalization -- SNDX: $1.42B vs. YMAB: $590.77M
SNDX [@Biotechnology] is valued at $1.42B. YMAB’s [@Biotechnology] market capitalization is $590.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SNDX’s FA Score shows that 1 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • SNDX’s FA Score: 1 green, 4 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, SNDX is a better buy in the long-term than YMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SNDX’s TA Score shows that 5 TA indicator(s) are bullish while YMAB’s TA Score has 3 bullish TA indicator(s).

  • SNDX’s TA Score: 5 bullish, 5 bearish.
  • YMAB’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, SNDX is a better buy in the short-term than YMAB.

Price Growth

SNDX (@Biotechnology) experienced а -22.06% price change this week, while YMAB (@Biotechnology) price change was -15.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.97%. For the same industry, the average monthly price growth was +5.49%, and the average quarterly price growth was +6.49%.

Reported Earning Dates

SNDX is expected to report earnings on Mar 05, 2025.

YMAB is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-1.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($1.42B) has a higher market cap than YMAB($591M). YMAB YTD gains are higher at: 93.402 vs. SNDX (-22.999). YMAB has higher annual earnings (EBITDA): -27M vs. SNDX (-263.84M). SNDX has more cash in the bank: 432M vs. YMAB (77.8M). SNDX has less debt than YMAB: SNDX (1.13M) vs YMAB (1.27M). YMAB has higher revenues than SNDX: YMAB (86.5M) vs SNDX (3.5M).
SNDXYMABSNDX / YMAB
Capitalization1.42B591M240%
EBITDA-263.84M-27M977%
Gain YTD-22.99993.402-25%
P/E RatioN/AN/A-
Revenue3.5M86.5M4%
Total Cash432M77.8M555%
Total Debt1.13M1.27M89%
FUNDAMENTALS RATINGS
SNDX vs YMAB: Fundamental Ratings
SNDX
YMAB
OUTLOOK RATING
1..100
98
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
51100
SMR RATING
1..100
9693
PRICE GROWTH RATING
1..100
6341
P/E GROWTH RATING
1..100
5100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YMAB's Valuation (57) in the Pharmaceuticals Major industry is in the same range as SNDX (85) in the Biotechnology industry. This means that YMAB’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's Profit vs Risk Rating (51) in the Biotechnology industry is somewhat better than the same rating for YMAB (100) in the Pharmaceuticals Major industry. This means that SNDX’s stock grew somewhat faster than YMAB’s over the last 12 months.

YMAB's SMR Rating (93) in the Pharmaceuticals Major industry is in the same range as SNDX (96) in the Biotechnology industry. This means that YMAB’s stock grew similarly to SNDX’s over the last 12 months.

YMAB's Price Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as SNDX (63) in the Biotechnology industry. This means that YMAB’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for YMAB (100) in the Pharmaceuticals Major industry. This means that SNDX’s stock grew significantly faster than YMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SNDXYMAB
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
73%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Ad is loading...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
REIPX38.76N/A
N/A
T. Rowe Price Equity Income I
SPMPX6.05-0.01
-0.17%
Invesco SteelPath MLP Alpha Plus R5
COSTX10.46-0.07
-0.66%
Columbia Overseas Core Institutional 2
SGGDX27.31-0.33
-1.19%
First Eagle Gold A
OBEGX30.53-0.69
-2.21%
Oberweis Global Opportunities Investor

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with RCUS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then RCUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
+2.65%
RCUS - SNDX
49%
Loosely correlated
-2.03%
NGNE - SNDX
47%
Loosely correlated
-1.15%
RAPT - SNDX
45%
Loosely correlated
-9.77%
ABOS - SNDX
45%
Loosely correlated
-5.42%
BEAM - SNDX
45%
Loosely correlated
-1.57%
More